SHIFT Newsroom · GLOBAL
Nutrition during incretin treatment: what a 19-trial review found
A systematic review examines intake, body composition and reported malnutrition—not just weight loss.
What the authors report
The review brings together 19 randomised trials from the STEP, SURMOUNT, SCALE and OASIS programmes. It reports lower energy intake and changes in fat-free mass, alongside nutritional and laboratory outcomes.
Investigator-reported malnutrition was uncommon in the pooled reports, at 0.12%. The authors also discuss low lymphocyte counts and modelled energy deficits. Those are different measures; a laboratory marker is not, by itself, a diagnosis of malnutrition.
Limits of the findings
The medicines, populations and measurements vary. Fat-free mass is not synonymous with skeletal muscle, and pooled findings cannot predict an individual outcome. The authors propose a screening approach; publication does not make it an NHS guideline.
SHIFT’s take
The practical message is to assess nutrition alongside weight, without turning a review title into a claim that everyone using these medicines is malnourished.
Known facts
- The source is a systematic review and meta-analysis, not a new standalone treatment trial.